LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Akcijų sąrašas・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

20.32 -0.2

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

19.45

Max

20.46

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-607K -51M
Pardavimai	-28M 100M
Pelnas, tenkantis vienai akcijai	-0.46
Pelno marža	-51.215
Darbuotojai	1,784
EBITDA	4.1M -44M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+67.42% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-183M 2.2B
Ankstesnė atidarymo kaina	20.52
Ankstesnė uždarymo kaina	20.32

Naujienos nuotaikos

By Acuity

50%

162 / 346 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

28.13 / 31.12 Palaikymas ir pasipriešinimas

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-13 22:54; UTC

Uždarbis

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

2026-05-13 23:51; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-13 23:51; UTC

Rinkos pokalbiai

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

2026-05-13 23:45; UTC

Rinkos pokalbiai

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

2026-05-13 23:45; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-13 23:17; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

2026-05-13 23:16; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

2026-05-13 23:15; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

2026-05-13 23:14; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

2026-05-13 23:02; UTC

Rinkos pokalbiai

Uždarbis

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

2026-05-13 22:59; UTC

Rinkos pokalbiai

Uždarbis

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

2026-05-13 22:24; UTC

Uždarbis

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

2026-05-13 22:23; UTC

Uždarbis

Xero FY International Organic Revenue Growth 25%>XRO.AU

2026-05-13 22:23; UTC

Uždarbis

Xero FY International Revenue Growth 47%>XRO.AU

2026-05-13 22:22; UTC

Uždarbis

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

2026-05-13 22:19; UTC

Uždarbis

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

2026-05-13 22:19; UTC

Uždarbis

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

2026-05-13 22:18; UTC

Uždarbis

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

2026-05-13 22:16; UTC

Uždarbis

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

2026-05-13 22:15; UTC

Uždarbis

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

2026-05-13 22:15; UTC

Uždarbis

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

2026-05-13 22:13; UTC

Uždarbis

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

2026-05-13 22:12; UTC

Uždarbis

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

2026-05-13 22:11; UTC

Uždarbis

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

2026-05-13 22:11; UTC

Uždarbis

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

2026-05-13 22:10; UTC

Uždarbis

Xero Did Not Declare a Dividend>XRO.AU

2026-05-13 22:10; UTC

Uždarbis

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

2026-05-13 22:09; UTC

Uždarbis

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

2026-05-13 22:00; UTC

Uždarbis

Cisco to Shed Jobs for All-In AI Push -- Update

2026-05-13 21:11; UTC

Uždarbis

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

67.42% į viršų

12 mėnesių prognozė

Vidutinis 34.27 USD 67.42%

Aukščiausias 44 USD

Žemiausias 21.8 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Zai Lab Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

28.13 / 31.12Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

Rinkos nuotaikos

By Acuity

162 / 346 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.